Welcome to our dedicated page for Elevance Health SEC filings (Ticker: ELV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elevance Health, Inc. filings document formal disclosures for a health benefits and healthcare services company, including Form 8-K reports of quarterly and annual results, earnings guidance, benefit expense ratio updates, and Regulation FD communications. The filings also cover leadership changes, Carelon oversight, board appointments, committee assignments, and executive compensation matters reported through proxy materials.
Its regulatory documents include risk and operating disclosures tied to Health Benefits, Carelon, pharmacy and diversified healthcare services, provider contracting, product mix, government program funding, CMS Star Ratings, litigation, investigations, audits and professional-liability exposure. Recent 8-K disclosures also address CMS oversight of the company's Medicare Advantage-Prescription Drug plans.
DeVore Susan D. reported acquisition or exercise transactions in this Form 4 filing.
Elevance Health director Susan D. DeVore received an award of 563 deferred stock units of common stock on May 13. The grant was made at no cash cost as part of the company’s Board of Directors Compensation Program and increases her direct holdings to 4,065 shares-equivalent.
The deferred stock units will be settled in Elevance Health common stock upon the earlier of five years from the grant date or when she leaves the board, unless she has elected a later payment date under the Board of Directors Deferred Compensation Plan.
COLLIS STEVEN H reported acquisition or exercise transactions in this Form 4 filing.
Elevance Health director Steven H. Collis reported an award of 563 deferred stock units of common stock. The units were granted at no cash price as part of the company’s Board of Directors Compensation Program, increasing his directly held equity units to 4,202.
The deferred stock units will be settled in Elevance Health common stock upon the earlier of five years from the grant date or when Collis leaves the board, unless he has elected a later date under the Board of Directors Deferred Compensation Plan.
Elevance Health, Inc. reported results of its Annual Meeting of Shareholders held on May 13, 2026. A total of 194,441,339 common shares were represented, establishing a quorum. Three directors—Gail K. Boudreaux, Robert L. Dixon, Jr., and Deanna D. Strable—were elected to three-year terms ending at the 2029 annual meeting.
Shareholders approved, on an advisory basis, the compensation of the company’s named executive officers, with 172,363,616 votes for and 7,240,619 against. They also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 175,183,332 votes for and 19,141,697 against.
A shareholder proposal requesting an independent study on the impact of prohibiting corporate contributions to partisan 527 tax-exempt political groups did not pass, receiving 15,587,160 votes for and 162,924,290 votes against.
Elevance Health Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 16,601,224 shares of Common Stock, representing 7.13% of the class as of 03/31/2026. The filer reports sole dispositive power over 16,601,224 shares and sole voting power for 2,255,765 shares. The filing is signed on 04/29/2026.
Elevance Health reported higher first-quarter 2026 revenue but lower profit as it absorbed large Medicare and restructuring charges. Total revenues rose to $50.2 billion from $48.9 billion a year earlier, driven mainly by premiums of $41.0 billion and product revenue of $6.2 billion.
Net income fell to $1.8 billion from $2.2 billion, with diluted earnings per share declining to $8.00 from $9.61. Results included a $935 million accrual tied to Medicare Advantage risk-adjustment data the company previously submitted to CMS, where the ultimate liability could be between $585 million lower and $565 million higher than the amount accrued. Elevance also booked $129 million of costs under a new 2026–2027 Operating Model Transformation Program aimed at simplifying its organization and expanding technology use.
Despite these charges, operations generated $4.3 billion of cash, up sharply from $1.0 billion a year earlier. The company repurchased 3.7 million shares for $1.1 billion at an average price of $304.68 and paid dividends of $1.72 per share, while total shareholders’ equity held roughly steady at $43.9 billion.
Elevance Health reported first quarter 2026 results ahead of expectations and raised its full-year outlook. Operating revenue was $49.5 billion, up 1.5% year over year, driven by higher premium yields in Health Benefits and growth in CarelonRx product revenue.
GAAP diluted EPS was $8.00, down 16.8% as net income fell 19.4%, largely reflecting a $935 million accrual tied to a CMS notice and $129 million in business optimization charges. Adjusted diluted EPS rose to $12.58, up 5.1%, helped by strong operations and about $1 per share of non-recurring investment income.
Operating cash flow surged to $4.3 billion, versus $1.0 billion a year ago. The company reaffirmed 2026 operating cash flow of at least $5.5 billion, raised 2026 adjusted diluted EPS guidance to at least $26.75, and now expects GAAP diluted EPS of at least $19.85. Elevance returned $1.5 billion to shareholders in the quarter via 3.7 million share repurchases and a $1.72 per-share dividend.
Trillium Asset Management urges Elevance Health shareholders to vote FOR Item #4, a proposal requesting the Board commission an independent study on prohibiting corporate contributions to partisan 527 political organizations. Trillium cites prior spending—$2.1 million in 2024 and $1.6 million in H1 2025 on 527s—and argues an independent assessment would clarify whether such treasury contributions serve long-term shareholder interests.
Elevance Health is asking shareholders to vote at the virtual 2026 Annual Meeting on May 13, 2026, on four proposals, including electing three directors, approving executive pay, ratifying Ernst & Young as auditor, and opposing a political-spending study proposal. The proxy highlights 2025 operating revenue of $197.6 billion, up 13%, operating gain of $7.2 billion, GAAP shareholders’ net income of $5.7 billion and adjusted shareholders’ net income of $6.8 billion. The company returned $4.1 billion to shareholders and paid cash dividends of $6.84 per share, a 5% increase, ending the year with about 45.2 million medical members. The Board emphasizes independent oversight, strong risk and AI governance, sustainability commitments and pay-for-performance, with most executive compensation tied to long-term equity and financial metrics.
The Vanguard Group filed Amendment No. 11 to a Schedule 13G/A reporting 0 shares and 0% beneficial ownership of Elevance Health Inc common stock. The filing states that, following an internal realignment effective January 12, 2026, certain Vanguard subsidiaries will report ownership separately in reliance on SEC Release No. 34-39538.
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Elevance Health, Inc. director Amy W. Schulman reported an open-market sale of common stock. On March 12, 2026, she sold 26 shares of Elevance Health common stock at a price of $287.50 per share. After this transaction, she directly owns 218 shares of Elevance Health common stock.